Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Autonomic Nervous System Diseases
  • Immunoglobulin M
  • Paraproteinemias

abstract

  • Rituximab, a monoclonal antibody against B-cell membrane marker CD-20, is an effective treatment for immunoglobulin M (IgM) monoclonal anti-myelin-associated glycoprotein (MAG) neuropathies. We report a patient with an autonomic and painful sensory neuropathy associated with an IgM lambda monoclonal gammopathy, responsive to rituximab. Treatment resulted in a decline in total IgM and improvement in the patient's painful neuropathy and dysautonomia. Rituximab may be an effective and tolerable treatment for autonomic and sensory neuropathy associated with IgM monoclonal gammopathy.

publication date

  • April 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/mus.20244

PubMed ID

  • 15685616

Additional Document Info

start page

  • 510

end page

  • 5

volume

  • 31

number

  • 4